Amongst FDCSs, the average Apgars at 1 and 5-minutes were 8.6 and 8.8 respectively. 4/40(10%) had a 1-minute Apgar of ?5, 2/40(5%) had a 5-minute Apgar of ?5. Amongst ECSs, the average Apgars at 1 and 5-minutes were 8.5 and 8.9 respectively. 22/549(4%) had a 1-minute Apgar of ?5, 3/549(0.5%) had a 5-minute Apgar of ?5.
HUMAN MILK BANKING -A PARTNERSHIP BETWEEN PARENTS AND CLINICIANS TO IDENTIFY AND PRIORITIZE THE 10 TOP RESEARCH PRIORITIES
Background: The re-emergence of human milk banking in Australia has highlighted the many research questions that exist regarding milk banking and the use of donor human milk. It therefore is timely to set research priorities that consider the key questions from those to whom it matters most: parents of preterm infants, potential milk donors and clinicians. This study sought to identify the top ten research priorities for human milk banking and use of donor milk.
Methods: A consensus approach modelled on the James Lind Alliance was used. A steering group and a national partnership was formed between key stakeholders. Research uncertanties were gathered through an online survey and literature search. An iterative process was used to consolidate and rank questions. A final workshop was held to identify the top 10 research priorities.
Results: 398 research uncertainties were gathered (65% clinicians, 32% parents/milk donors, 3% literature) from 203 survey respondents and literature. The Steering Group consolidated these to 39 research uncertainties, which were ranked via another survey. The top 24 questions were workshopped by 13 participants (4 parents/milk donors and 9 clinicians) to determine the top 10 research priorities. These included the risks and benefits of using donor milk, optimal techniques for processing and the effects of these on the properties of milk, the nutrient profile of the milk and clinical criteria for prioritising receipt of milk.
Conclusion:
The top 10 research priorities in human milk banking and use of donor milk were identified and can be used to guide researchers. University of New South Wales Background: Recently, clinical trials have reported safety and efficacy data for the treatment of established cerebral palsy (CP) using umbilical cord blood (UCB). UCB contains many cell types, including endothelial progenitor cells (EPCs), T-regulatory cells (Tregs) and suppressive monocytes. However, it is unknown how each cell type contributes towards the neuroprotective benefits of UCB. Here we examined administration of specific cell types early after injury in a rodent model of hypoxic-ischemic (HI) encephalopathy.
WHAT IS SO SPECIAL ABOUT UMBILICAL CORD BLOOD: UNDERSTANDING THE ROLE OF DIFFERENT CELLS IN PREVENTING CEREBRAL PALSY
Methods: Human UCB mononuclear cells, EPCs, Tregs and monocytes were isolated from term UCB. HI-injury was induced in postnatal day 7 rats, via carotid artery ligation followed by 3 h of 8% oxygen. Cells were administered 24 h later (IP), and brains were collected at 7d or 50d post HI. Immunohistopathology was performed on brain sections to assess neurons (NeuN), cell death (Tunel), inflammation (IBA-1), microglia phenotype (mannose), astrocytes (GFAP) and vasculature (RECA).
Results: At 7d post HI-injury, all UCB cell types studied reduced cell death, neuronal loss and inflammation in the brain, but to different degrees. Interestingly, while inflammation was reduced at 7d following cell treatment, at 50d, activation of microglia was significantly increased in all cell-treated groups compared to HI and sham rats.
Conclusions: Our work suggests that cells found in UCB mediate neuroprotection through different pathways, and may have complimentary actions. Further studies will examine the mechanistic target and neuroprotective actions of each individual cell type. This work has the potential to develop tailored UCB early intervention therapies for reducing perinatal brain injury and CP. 
RESUMPTION OF SEX AFTER FIRST AND SECOND BIRTHS: DISPELLING THE MYTH THAT EVERYTHING IS

Murdoch Childrens Research Institute
Objective: To investigate the timing of resumption of sex after first and second births and assess associations with method of birth.
Design: Prospective pregnancy cohort of 1507 nulliparous women recruited in early pregnancy and followed up: 3, 6, and 12 months after their 1 st birth; and 6 and 12 months after 2 nd and subsequent births. Results: 41% percent of first time mothers (342/1305) and 34% of women having a second baby (205/893) resumed sex by 6 weeks postpartum. By 8 weeks postpartum, 65% of women having their first baby and 56% of women having their second baby had resumed sex, increasing to 78% at 12 weeks and 94% by 6 months postpartum among first time mothers, and 76% at 12 weeks and 87% at 6 months postpartum among mothers having their second child. Compared with women who had a spontaneous vaginal birth and intact perineum, women who had an operative vaginal birth (Adj. OR 4.60, 95% CI [1.6-13.6]) and women who had a caesarean section (Adj. OR 1.99, 95% CI [1.3-3.1]) were less likely to have resumed sex by 6 weeks postpartum.
Conclusion: Counter to the myth that most women are 'back to normal' by 6 weeks, less than half of women having their first baby and around only around a third of women having their second baby resume sex by 6 weeks postpartum. Women who had an operative vaginal birth in a first or second birth were the most likely to delay resumption of sex. Division of Oncology, Washington University Adequate lung development is vital for survival at birth. We have previously shown that the gene Trop2 is expressed in airway and alveolar epithelial cells, smooth muscle cells, endothelial cells and fibroblast cells in the fetal lung and that Trop2 controls the proliferation and migration of cultured fetal lung myofibroblasts. We hypothesised that mice that lack the Trop2 gene would have altered alveolar and airway development. The lungs of Trop2-null mice and wild-type controls were collected at postnatal day (P)10 and P20. Tissue:airspace ratio, secondary septal crest density, elastin content, cell proliferation, myofibroblast density, smooth muscle density and tight junction organisation were measured using immunohistochemistry. Tight junction protein claudin-1 levels were measured using western blots. Trop2-null mice at P10 had a 25% increase in airway smooth muscle density (p = 0.02), but no change in tissue:airspace ratio. At P10, there was no change in the protein level of claudin-1 but it was abnormally distributed in the airway epithelial cells in Trop2-null mice. At P20, the proliferation of airway epithelial cells was increased by 30% (p = 0.03) and airway smooth muscle density was significantly decreased by 40% (p = 0.049) in Trop2-null mice compared to controls. There was no change in tissue:airspace ratio, myofibroblast density, secondary septal crest density, airway elastin content or cell proliferation in the parenchyma. Loss of Trop2 results in altered development of the airways, but has no effect on alveolar development. The altered distribution of claudin-1 suggests that tight junction organisation is altered in Trop2-null mice, which may affect barrier function.
LOSS OF TROP2 ALTERS
